Login
Evidence Feed
About
Diagnostics
New
FAQ
Contact us
^
Login
Contact us
to learn more about
our Premium Content: News alerts, weekly reports and conference planners
DRUG:
LENZ (lenzilumab)
i
Other names:
KB003, KB-003, KB 003
Contact us
to learn more about our Premium Content:
News alerts, weekly reports and conference planners
Associations
(3)
News
Trials
Company:
Humanigen, Taran Therapeutics, Telcon
Drug class:
GM-CSF inhibitor
‹
›
Associations
(3)
News
Trials
VERI cancer hierarchy
Reset Filters
NRAS mutation
Chronic Myelomonocytic Leukemia
NRAS mutation
Chronic Myelomonocytic Leukemia
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
CBL mutation
Chronic Myelomonocytic Leukemia
CBL mutation
Chronic Myelomonocytic Leukemia
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
KRAS mutation
Chronic Myelomonocytic Leukemia
KRAS mutation
Chronic Myelomonocytic Leukemia
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
lenzilumab
Sensitive: C2 – Inclusion Criteria
lenzilumab
Sensitive
:
C2
^
^
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.
×
Unlock More with VERI
Sign up to access premium content
Email *
Password *
Confirm Password *
I'm not a robot
Please register with your email ID.